Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Trump Criticizes Rep. Al Green as ‘Embarrassment’ to Democrats, Calls for IQ Test

March 6, 2025

Signal Faces Challenges as Trump Administration Supports National Security Advisor

April 4, 2025

Trump Administration Unable to Deport Family of Colorado Attack Suspect

June 4, 2025

Donald Trump Jr. Emerges as Influential Figure in Washington

May 15, 2025

Trump Criticizes ‘Rebel’ Republicans for Poor Negotiation on Tariffs

April 9, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • U.S. Targets Iran Nuclear Sites Amid Diplomatic Tensions with Israel
  • Iran Warns of Potential Responses Following U.S. Strikes on Nuclear Sites
  • Israeli Missile Strikes Leave Over a Dozen Injured
  • District Centers Formed for Tail Development Amidst 4 Million People Facing Growth Challenges
  • California Senate Insurance Committee Appoints New Leader Amid Corruption Investigation
  • Tensions Between Israel and Iran Heighten, Impacting Energy Supply in Europe
  • Retired General Praises Trump’s Actions Amid U.S. Strikes on Iran
  • World Leaders Respond to U.S. Airstrikes on Iranian Nuclear Sites
  • Decades-Later Diplomas Awarded to Vietnam Veterans Who Left High School for Service
  • Rising Tariffs Drive Up Remodeling Costs: Strategies for Savings
  • Lawmakers React to U.S. Strikes on Iranian Nuclear Sites
  • Belarus Releases Jailed Opposition Leader and Dozens Following U.S. Diplomatic Visit
  • Study Finds AI Bots May Contribute to Cognitive Decline
  • Trump Declares Success in Strikes on Iranian Nuclear Facilities
  • Pelley Family Tragedy: Friendship Rekindled After Prom Night Murders
  • U.S. Strikes Target Three Iranian Nuclear Facilities, Trump Responds
  • From Oktay Saral to Tanju Özcan: ‘Your Water Is Ready’
  • Fire During Flight Causes Hot-Air Balloon Crash in Brazil, Resulting in Eight Fatalities
  • Republican Party Outpaces Democrats with Nearly Fivefold Cash Advantage
  • US Deploys B-2 Bombers to Guam Amid Rising Mideast Tensions
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Sunday, June 22
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Business » Moderna (MRNA) Q4 earnings 2024
Moderna (MRNA) Q4 earnings 2024

Moderna (MRNA) Q4 earnings 2024

News EditorBy News EditorFebruary 19, 2025 Business 5 Mins Read

Moderna has reported its fourth-quarter financial results for 2024, revealing a net loss that surpassed analyst expectations, despite revenue exceeding estimates. The biotech firm continues to grapple with a significant decrease in demand for its Covid-19 vaccine as it shifts focus toward new product development. The company aims to reduce costs further and anticipates more regulatory approvals for innovative treatments in the near future. Shares of Moderna saw an increase of over 3% on the day of the announcement.

Article Subheadings
1) Overview of Financial Performance
2) Cost-Cutting Measures and Future Expectations
3) Revenue Breakdown from Covid and RSV Vaccines
4) Pipeline of New Products and Approvals
5) Market Response and Future Outlook

Overview of Financial Performance

In its latest quarterly report, Moderna revealed a net loss of $1.12 billion for the fourth quarter of 2024, equivalent to losses of $2.91 per share. This is a steep decline from a net income of $217 million, or 55 cents per share, recorded in the same quarter of the previous year. Despite the substantial losses, the reported revenue of $966 million narrowly beat analyst expectations of $942.8 million, marking a significant decrease from the $2.8 billion generated during the corresponding period last year. The losses were characterized by a $238 million noncash charge linked to the termination of a contract manufacturing agreement, highlighting the ongoing challenges facing the organization as it transitions from a Covid-focused portfolio to broader therapeutic offerings.

Cost-Cutting Measures and Future Expectations

Looking ahead, Moderna’s Chief Financial Officer, Jamey Mock, noted that the company successfully achieved a 27% reduction in costs over the prior year and aims to further enhance its savings by $1 billion by the end of 2025. This turnaround strategy is essential as the company navigates declining Covid vaccine demand and a competitive landscape laden with pricing pressures and changes in government policies surrounding vaccinations. Moderna has reiterated its sales guidance for 2025, suggesting a projected revenue range of $1.5 billion to $2.5 billion, with the majority expected to arrive in the latter half of the year due to seasonal demand patterns for respiratory products.

Revenue Breakdown from Covid and RSV Vaccines

A significant portion of Moderna’s recent revenue was derived from its Covid-19 vaccine, which netted $923 million, representing a staggering 66% year-over-year decline. The U.S. sector accounted for $244 million, with international sales contributing $679 million. Analysts had predicted the Covid shot would generate $909 million, underscoring the shrinking market as vaccination rates decrease. Alongside the Covid vaccine, Moderna reported $15 million in sales from its newly-approved respiratory syncytial virus (RSV) vaccine targeted at adults over the age of 60, which began its rollout after receiving FDA clearance.

Pipeline of New Products and Approvals

Moderna’s future plans hinge on expanding its product pipeline, which leverages its messenger RNA technology. The company aims to secure approval for ten new products over the next three years. Currently, three mRNA products have been submitted for regulatory approval, including a next-generation covid vaccine and a combination shot addressing both Covid and flu viruses. The FDA is expected to issue a decision on the next-generation Covid vaccine by May, with further developments anticipated for the RSV shot in June. Additional projects include a stand-alone flu vaccine and a personalized cancer treatment in collaboration with Merck, as well as products targeting latent viruses.

Market Response and Future Outlook

Despite the initial negative market sentiment resulting from Moderna’s cut to its sales guidance earlier in the year, which caused shares to drop by more than 20%, the company’s stock rose by more than 3% following the latest earnings report. While headwinds remain—such as increased competition in the Covid vaccine arena and uncertain advisory recommendations regarding respiratory syncytial virus vaccination—the company remains optimistic about counteracting these challenges and returning to a growth trajectory. Continued market engagement and innovative product development will be crucial for Moderna as it transitions from pandemic-era revenue sources to a more diversified pharmaceutical portfolio.

No. Key Points
1 Moderna reported a net loss of $1.12 billion for Q4 2024.
2 Revenue exceeded expectations at $966 million, but was less than half of $2.8 billion from a year ago.
3 Moderna aims to reduce costs by an additional $1 billion by 2025.
4 The Covid vaccine generated $923 million in revenue, down 66% from the previous year.
5 Moderna plans to launch ten new products over the next three years based on mRNA technology.

Summary

Moderna’s recent financial results underscore the challenges the company faces as it adapts to a post-Covid world. Despite a significant net loss and declining vaccine sales, the company’s proactive cost-cutting measures and commitment to innovation suggest a strategic pivot toward a more diversified pharmaceutical future. The upcoming regulatory decisions on new products will be critical as Moderna strives to regain momentum and establish a sustainable growth path post-pandemic.

Frequently Asked Questions

Question: Why did Moderna report significant losses in Q4 2024?

Moderna experienced a net loss largely due to reduced sales from its Covid-19 vaccine, as demand has significantly declined. Additionally, the company faced a noncash charge impacting financial performance.

Question: What strategies is Moderna employing to reduce costs?

The company successfully reduced costs by 27% compared to the previous year and aims to cut another $1 billion in costs by the end of 2025 through various operational efficiencies.

Question: What is next for Moderna’s product development?

Moderna plans to expand its product lineup with ten new approvals over the next three years, focusing on mRNA technology to develop vaccines and treatments for respiratory diseases and other conditions.

Business Ethics Business Growth Business News Business Technology Consumer Trends Corporate Finance Corporate Strategy earnings Economic Outlook Entrepreneurship Global Business Innovation Investment Opportunities Leadership Management Market Trends Mergers & Acquisitions Moderna MRNA Retail Business Small Business Startups Supply Chain
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

Private Jet Flight Patterns Shift as Demand Evolves

6 Mins Read
Business

Kroger Reports Q1 2025 Earnings Results

6 Mins Read
Business

Darden Restaurants Reports Q4 2025 Earnings Results

5 Mins Read
Business

U.S. Gains 1,000 New Millionaires Daily in 2024

6 Mins Read
Business

Nike Delays Skims Launch with Kim Kardashian

4 Mins Read
Business

Lakers Owners Sell Majority Stake Valued at $10 Billion

6 Mins Read
Mr Serdar Avatar

Serdar Imren

News Director

Facebook Twitter Instagram
Journalism Under Siege
Editors Picks

Trump Asserts Right to “Remove People” Under Habeas Corpus

May 20, 2025

Judge Dismisses Trump’s Legal Challenge to U.S. Institute of Peace

May 19, 2025

Trump Encourages Migrants to Use DHS CBP Home App for ‘Self-Deportation’

March 18, 2025

CDC Will Attend WHO Vaccine Conference Amid Trump Executive Order

February 26, 2025

Chinese Couple Faces Charges for Smuggling Biological Pathogen into U.S.

June 3, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.